

## **RESOLUTION**

### **On the implementation of the share issuance plan to pay 2025 dividends**

#### **THE BOARD OF DIRECTORS**

#### **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and its amending and supplementing documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, and its amending and supplementing documents;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 detailing a number of articles of the Law on Securities, as amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020 of the Ministry of Finance guiding offerings, issuance of securities, public tender offers, share repurchases, registration and deregistration of public companies;
- Pursuant to the Resolution of the 2026 Annual General Meeting of Shareholders No. 01/NQ-NQ-AGP.DHD CD dated March 27, 2026;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. 01/BB-AGP.DHD CD dated March 27, 2026;
- Pursuant to Proposal No. 02/TT-AGP.DHD CD dated March 3, 2026 on profit distribution and dividend payment for 2025;
- Pursuant to Proposal No. 05/TT-AGP.DHD CD dated March 3, 2026 on the share issuance plan to pay 2025 dividends;
- Pursuant to the Minutes of the Board of Directors Meeting No. 05/BB-AGP.HDQT dated April 06, 2026;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company (the “Company”).

#### **RESOLVES:**

**Article 1:** To approve the implementation of the share issuance plan for the 2025 dividend payment as approved by the 2026 Annual General Meeting of Shareholders on March 27, 2026, with the following details:

- 1. Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
- 2. Share type:** Common shares
- 3. Par value:** VND 10,000/share
- 4. Current charter capital:** VND 306,075,580,000
- 5. Total number of issued shares:** 30,607,558 shares

Of which:

- Total number of outstanding shares: 30,607,558 shares

- Total number of treasury shares: 0 shares

6. **Estimated number of shares to be issued:** 3,672,906 shares
7. **Total value of issuance at par value:** 36.729.060.000 đồng
8. **Eligible subscriber:** Existing shareholders whose names appear on the final shareholder list as of the record date. The record date for the shareholder list will be determined by the Board of Directors, as authorized by the General Meeting of Shareholders.
9. **Issuance ratio** (estimated number of shares to be issued/number of outstanding shares): 12%
10. **Subscription ratio:** 25:03. For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 25 rights will entitle the shareholder to 3 additional new shares.
11. **Source of capital:** Retained earnings after tax as of December 31, 2025, based on the audited financial statements for the year 2025 of Agimexpharm Pharmaceutical Joint Stock Company.
12. **Issuance method:** The shares issued to existing shareholders will be distributed through the exercise of subscription rights.
13. **Plan to handle the fractional shares:** The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 122 shares as of the record date. With a subscription ratio of 25:03, Shareholder A is entitled to receive  $(122 \times 3/25) = 14.64$  new shares. Following this calculation method, Shareholder A will receive 14 additional shares, and the fractional portion of 0.64 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

14. **Expected time of issuance:** After the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2026.
15. **Additional securities registration and additional trading registration:** The GMS approves and authorizes the BOD to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.
16. **Approval of charter capital increase:** Approval of amendments to the Company's Charter (Charter Capital section) and adjustment of the Enterprise Registration Certificate at the competent authority after the State Securities Commission of Vietnam confirms in writing the receipt of the issuance result report.

**Article 2:** The Board of Directors assigns the General Director to implement the share issuance plan for dividend payment, including:

- Completing and submitting the application dossier for share issuance to the State Securities Commission of Vietnam and providing explanations when required;

- Preparing and submitting to the Board of Directors for approval all documents related to additional securities registration at VSDC – Ho Chi Minh City Branch and additional trading registration at HNX after obtaining approval from the State Securities Commission;
- Carrying out information disclosure in accordance with applicable laws.


**Article 3:** Members of the Board of Directors and the Executive Board of Agimexpharm Pharmaceutical Joint Stock Company are responsible for implementing this Resolution.

This Resolution takes effect from the date of signing.

***Recipients:***

- As stated in Article 3;
- Archived: BOD Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRWOMAN**



**PHARM. PHAM THI BICH THUY**

**RESOLUTION**

**On approval of the implementation procedures for securities offering and issuance**

**THE BOARD OF DIRECTORS**

**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and its amending and supplementing documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, and its amending and supplementing documents;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 detailing a number of articles of the Law on Securities, as amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;
- Pursuant to Circular No. 118/2020/TT-BTC dated December 31, 2020 of the Ministry of Finance guiding offerings, issuance of securities, public tender offers, share repurchases, registration and deregistration of public companies;
- Pursuant to the Resolution of the 2026 Annual General Meeting of Shareholders No. 01/NQ-NQ-AGP.DHDCD dated March 27, 2026;
- Pursuant to the Minutes of the 2026 Annual General Meeting of Shareholders No. 01/BB-AGP.DHDCD dated March 27, 2026;
- Pursuant to Proposal No. 02/TT-AGP.DHDCD dated March 3, 2026 on profit distribution and dividend payment for 2025;
- Pursuant to Proposal No. 05/TT-AGP.DHDCD dated March 3, 2026 on the share issuance plan to pay 2025 dividends;
- Pursuant to Proposal No. 06/TT-AGP.DHDCD dated March 3, 2026 on the share issuance plan under the Employee Stock Ownership Plan (ESOP);
- Pursuant to the Minutes of the Board of Directors Meeting No. 05/BB-AGP.HDQT dated April 06, 2026;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company (the “Company”).

**RESOLVES:**

**Article 1:** Approval of the implementation plan as follows:

Content	Number of shares
<b>A. Number of shares before issuance</b>	<b>30,607,558 shares</b>
Total issued shares	30,607,558 shares
Total outstanding shares	30,607,558 shares
<b>B. Number of shares expected to be issued</b>	<b>5,203,283 shares</b>

Content	Number of shares
Shares to be issued for dividend payment (12%)	3,672,906 shares
Shares to be issued under the Employee Stock Ownership Plan (ESOP) (5%)	1,530,377 shares
<b>C. Number of shares after issuance</b>	<b>35,810,841 shares</b>

The record date for determining shareholders entitled to receive the 2025 dividend payment shall be set prior to the commencement date of subscription payment for shares issued under the Employee Stock Ownership Plan (ESOP). Accordingly, shares issued under the ESOP shall not be entitled to receive shares from the 2025 dividend share issuance.

**Article 2:** To approve the procedures of implementation of the securities offerings and issuances to ensure that the share issuance for dividend payment and the ESOP issuance are conducted in accordance with the plan approved by the 2026 Annual General Meeting of Shareholders on March 27, 2026, as detailed in the Appendix attached to this Resolution.

**Article 3:** To authorize the Chairwoman of the Board of Directors, on behalf of the Board, to execute all relevant documents and direct the implementation of subsequent steps in compliance with applicable regulations.

**Article 4:** Members of the Board of Directors and the Executive Board of Agimexpharm Pharmaceutical Joint Stock Company are responsible for implementing this Resolution.

This Resolution takes effect from the date of signing.

***Recipients:***


- As stated in Article 4;
- Archived: BOD Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRWOMAN**



**PHARM. PHAM THI BICH THUY**

## APPENDIX



### PROPOSED TIMELINE FOR IMPLEMENTATION OF SHARE ISSUANCE FOR DIVIDEND PAYMENT AND ESOP ISSUANCE IN ACCORDANCE WITH THE PLAN

**APPROVED BY THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MARCH 27, 2026**

*(Attached to Resolution No. 07/NQ-AGP.HDQT dated April 06, 2026)*

No.	Content	Timeline (Business days)	Notes
1	SSC acknowledges receipt of complete issuance dossier	T	
2	Disclosure of issuance notice (dividend shares & ESOP)	T+3	Within 07 working days from SSC confirmation
3	Disclosure of BOD Resolution on record date	T+6	At least 10 days before record date
4	Announcement of record date	T+6	
5	Record date for dividend share entitlement	T+17	
6	Start date for ESOP subscription payment	T+18	
7	Report on dividend share issuance results	T+22	Within 15 days from completion (record date)
8	Disclosure of updated outstanding shares (post dividend issuance)	T+22	
9	End date for ESOP subscription payment	T+25	
10	SSC confirmation of receipt of dividend issuance results report	T+25	
11	Report on ESOP issuance results	T+32	Within 10 days from completion
12	Disclosure of updated outstanding shares (post ESOP)	T+32	
13	SSC confirmation of receipt of ESOP issuance results report	T+35	Within 03 working days
14	Request for release of escrow account (ESOP proceeds)	T+37	
15	Additional securities registration at VSDC (HCMC Branch)	T+37	Within 30 days from completion
16	Amendment of trading registration at HNX (UPCoM)	T+37	Within 30 days from SSC approval
17	VSDC – HCM Branch issues amended securities registration certificate	T+42	Within 05 working days
18	HNX issues approval for change in trading registration	T+43	Within 05 working days
19	Registration of first trading date for newly issued shares	T+48	Within 05 working days from HNX approval